Medications

Tislelizumab plus chemo slows advanced squamous NSCLC

(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...

Oncology & Cancer

Novel index IDs prognosis in adults with Burkitt lymphoma

(HealthDay)—The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal ...

Oncology & Cancer

Nivolumab effective treatment for malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung ...

Medications

Adding subcutaneous daratumumab slows advanced multiple myeloma

(HealthDay)—For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to ...

Medications

Pembrolizumab slows MSI-H-dMMR metastatic CRC

(HealthDay)—For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free ...

page 3 from 10